Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089421 · ClinicalTrials.gov registry record · NA
Genetic Information Assistant in Telegenetics
A NA study of Genetic Predisposition and Gene Mutation-Related Cancer, sponsored by University of Virginia.
- Recruiting
- Registry status
- NA
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT06089421: Recruiting NA study of Genetic Predisposition and Gene Mutation-Related Cancer, sponsored by University of Virginia.
NCT06089421 is a NA study of Genetic Predisposition and Gene Mutation-Related Cancer that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 96 participants, below the 3,513-participant average among 14 other Genetic Predisposition trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06089421, a NA study of Genetic Predisposition and Gene Mutation-Related Cancer, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is: • Does receiving pre-genetic test education with a chat bot or genetic counselor affect if the participant decides to get genetic testing? Participants will: * have a pre-test genetic counselling session with a genetic counselor or the GIA chatbot * answer questions about their cancer genetic knowledge and how they are doing * provide a saliva sample for genetic testing to test for cancer gene mutations * have their genetic testing results provided to them. * have the option to share their genetic testing results with family members Researchers will compare how many participants who had pre-genetic counseling with the chatbot received genetic testing to how many participants who had pre-genetic counseling with a genetic counselor received genetic testing.
Primary Outcome
dichotomous measurement of whether the randomized participant completes genetic testing within three months.
Conditions Studied
Interventions
- OTHER Genetic Information Assistant
- OTHER Telegenetics with UVA genetic counselor
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2027-08-01 |
| Phase | NA |
What NCT06089421 shows while recruiting
NCT06089421 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 3,513-participant average among 14 other Genetic Predisposition trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Genetic Predisposition appearing as the primary indexed condition, and to 2 interventions - of which Genetic Information Assistant is the first listed.
NCT06089421 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06089421 about?
NCT06089421 is a clinical study titled "Genetic Information Assistant in Telegenetics". The goal of this clinical trial is to learn about different ways cancer genetic screening can be provided to rural communities in participants at high risk for certain cancers. The main question it aims to answer is: • Does receiving pre-genetic test education with a chat bot or genetic counselor a...
What is the current status of trial NCT06089421?
This trial is currently recruiting. It is a NA study. The enrollment target is 96 participants. The study started on 2025-04-01. Estimated completion is 2027-08-01.
What conditions does trial NCT06089421 study?
This clinical trial studies the following conditions: Genetic Predisposition, Gene Mutation-Related Cancer.
What interventions are being tested in trial NCT06089421?
The interventions under investigation include: Genetic Information Assistant (OTHER), Telegenetics with UVA genetic counselor (OTHER).
Who is sponsoring clinical trial NCT06089421?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06089421 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Predisposition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06089421's enrollment target sits among peer trials
96 12th of 14 higher than 3 of 14 other Genetic Predisposition trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Genetic Predisposition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
RECRUITING · NA
-
Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing
RECRUITING · NA
-
Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes
ACTIVE NOT RECRUITING · NA
-
Overcoming Barriers to Accessing Genetic Medicine
ACTIVE NOT RECRUITING · NA
-
Early Detection of GEnetic Risk (EDGE)
COMPLETED · NA
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI